Obizur Prevents Bleeding in Surgery for Patient With Acquired Hem A
Obizur (susoctocog alfa), a pig-derived replacement therapy, can be used to prevent bleeding in people with acquired hemophilia…
Articles by Marisa Wexler, MS
EMA Speeds Approval Process for Hemophilia B Gene Therapy
The European Medicines Agency (EMA) has approved an accelerated assessment request for etranacogene dezaparvovec, an experimental gene therapy for…
Fitusiran Reduced Bleeding Regardless of Inhibitor Status
Monthly treatment with the investigational medication fitusiran can reduce bleeding in people with hemophilia A and B, with…
Amarna Raises Over $5M to Advance Gene Therapy for Hemophilia B
Amarna Therapeutics has secured €5 million (about $5.6 million) in new funding, which it plans to use for developing…
Hem A Patient in SIG-001 Trial Had Scarring in Delivery Spheres
In the first clinical trial of the experimental therapy SIG-001 for hemophilia A, one patient developed scarring in the…
Hemlibra Helps to Prevent Bleeds in Mild, Moderate Hem A, Data Show
Preventive treatment with Hemlibra (emicizumab) is safe and can effectively prevent bleeds in people with mild or moderate…
Regulators in Japan Asked to Extend Hemlibra to Acquired Hemophilia A
Chugai Pharmaceutical is asking regulatory authorities in Japan to extend the use of Hemlibra (emicizumab) in preventing or reducing…
Child With Inhibitors Against Alprolix Returns to Therapy After ITI
The first documented case of a previously untreated hemophilia B patient developing inhibitors against the extended half-life therapy…
Poseida, Takeda Aim to Develop Non-viral Gene Therapies for Hemophilia
Poseida Therapeutics and Takeda are working together to develop non-viral gene therapies for hemophilia and other genetic diseases. “Together…
‘Reverse Vaccination’ May Help Prevent Immune Response
A newly designed platform based on the principle of “reverse vaccination” could be used to prevent the development of an…